Physician profile
Ryan J Veurink
NPI 1447418322
$2,139.19
in general payments reported to CMS, 2019-2025
16 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $899 · 2021: $271 · 2022: $308 · 2023: $196 · 2024: $58.02 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medinc of Texas | $746.00 | 2020 | |
| Zimmer Biomet Holdings, INC. | $362.92 | 2021-2025 | Persona |
| Depuy Synthes Sales INC. | $240.68 | 2019-2025 | Monovisc, Orthovisc |
| Sanara Medtech INC. | $162.41 | 2023 | Celleraterx |
| Heraeus Medical, LLC. | $161.81 | 2020-2022 | |
| Next Science LLC | $86.05 | 2021 | |
| Kci USA, INC. | $84.29 | 2022 | |
| Stryker Corporation | $64.61 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $51.27 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $46.72 | 2023-2024 | Exparel, Zilretta |
| Smith+Nephew, INC. | $32.43 | 2019 | |
| Globus Medical, INC. | $29.63 | 2025 | Senza |
| Endo USA, INC. | $21.72 | 2025 | Xiaflex |
| Davol INC. | $20.50 | 2025 | Surgiphor |
| Pfizer INC. | $15.47 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Veurink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.